Organon & Co. Common Stock vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) trades at $24.82 (market cap $158.90B). The key difference: Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) is far larger — about 44× Organon & Co. Common Stock's market cap, and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) pays the higher dividend (2.35%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) for 6 Days on average.
| OGN | SMFG | |
|---|---|---|
Market Cap | $3.61B | $158.90B |
Volume | 1,808,049 | 1,175,519 |
Sector | Health | Financials |
52-Week High | $13.81 | $27.56 |
52-Week Low | $5.70 | $15.69 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.03B | $12.70T |
Dividend Yield | 0.58% | 2.35% |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SMFG trades at $25.21, up 0.72% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beating expectations with $0.50 EPS versus $0.44 expected, while Q4 2025 missed estimates. Revenue grew from $5.07T in 2025 to $6.14T in 2026 with net income margin improving to 27.8%. Analyst consensus shows 75% hold rating with institutional positions shifting recently.
SMFG presents a value opportunity with attractive valuation ratios (P/E 14.9, EV/EBITDA 5.16) and improving profitability, though technical weakness and mixed analyst sentiment suggest near-term caution. The stock faces risks from Japanese interest rate sensitivity and competitive pressures in global banking markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →Sumitomo Mitsui Financial Group is a Japanese financial services company with banking, securities, leasing, and asset management businesses. It serves retail, corporate, and institutional clients.
Read more on SMFG →